Click here to view cell apoptosis assay products
×

Recombinant Human BCMA/TNFRSF17 Protein (His Tag)

Uniprot : Q02223
  • Cat.No.:PKSH033486

  • Expression host: P.Pichia

To Purchase PKSH033486

Size:
  • 10µg
  • 50µg
Price: $92
Qty:

Description

Synonyms Tumor necrosis factor receptor superfamily member 17; B-cell maturation protein; CD269;TNFRSF17; BCM; BCMA
Species Human
Expression_host P.Pichia
Sequence Met1-Ala54
Accession Q02223
Mol_Mass 6.9 kDa
AP_Mol_Mass 12&15-28 kDa
Tag C-His

Properties

Purity > 90% as determined by reducing SDS-PAGE.
Endotoxin level < 1.0 EU per μg as determined by the LAL method.
Storage Lyophilized protein should be stored at < -20℃, though stable at room temperature for 3 weeks.Reconstituted protein solution can be stored at 4-7℃ for 2-7 days.Aliquots of reconstituted samples are stable at < -20℃ for 3 months.
Shipping This product is provided as lyophilized powder which is shipped with ice packs.
Formulation Lyophilized from a 0.2 μm filtered solution of PBS, pH7.4.
Reconstitution Please refer to the printed manual for detailed information.

Background

Tumor necrosis factor receptor superfamily, member 17 (TNFRSF17), also known as B cell maturation antigen (BCMA) or CD269 antigen, is a member of the TNF-receptor superfamily. This receptor is preferentially expressed in mature B lymphocytes, and may be important for B cell development and autoimmune response. This receptor has been shown to specifically bind to the tumor necrosis factor (ligand) superfamily, member 13b (TNFSF13BBAFF), and to lead to NF-kappaB and MAPK8/JNK activation. TNFRSF17/BCMA/CD269 also binds to various TRAF family members, and thus may transduce signals for cell survival and proliferation. TNFRSF17/BCMA/CD269 is a receptor for TALL-1 and BCMA activates NF-kappaB through a TRAF5-, TRAF6-, NIK-, and IKK-dependent pathway. The identification of TNFRSF17 as a NF-kappaB-activating receptor for TALL-1 suggests molecular targets for drug development against certain immunodeficient or autoimmune diseases. TNFRSF17/BCMA is a target of donor B-cell immunity in patients with myeloma who respond to DLI. Antibody responses to cell-surface BCMA may contribute directly to tumor rejection in vivo.

Related Products

Citations

From now on, if you have published a paper by using any of our products since 1/1/2019, fill out the “Elabscience Publication Reward Application Form”carefully and send it to orders@elabscience.com, we will get back to you with the reward after we confirm it ASAP!

View more details about our Publication Reward >>

Reviews/Q&A

  • Show all
  • Reviews
  • Q&A
... Show All Show Less

People Also Bought

Apply for
*Product Name:
*Catalog Number:
*Name:
*Email:
*Message:
*Country:
*When will you use it?

*Captcha: